PANDEMIC PROVIDER WEEKLY BROWN BAG

Updated May 3, 2022

ARIZONA DEPARTMENT OF HEALTH SERVICES
Health and Wellness for all Arizonans

Updates

The FDA has approved an amendment to the EUA for Pfizer Tris (Orange and Gray cap) COVID-19 vaccines extending the shelf-life from 9 to 12 months

Printed Manufacturing Date	12-Month Expiray Date
06/2021	31-May-2022
07/2021	30-Jun-2022
08/2021	31-Jul-2022
09/2021	31-Aug-2022
10/2021	30-Sep-2022
11/2021	31-Oct-2022
12/2021	30-Nov-2022
01/2022	31-Dec-2022
02/2022	31-Jan-2023
03/2022	28-Feb-2023

*Date of expiration always falls on the last day of the month

Please Note:

- **The QR code provided on the Pfizer Pediatric (orange cap) Vaccine carton provides a link to the EUA but does not provide information on expiration dates.**
- **No changes have been made to the vaccine itself to enable extension of expiry dating. This change is based on stability data submitted by the manufacturer to the FDA.**
- **COVID-19 vaccines authorized under an EUA do not have fixed expiration dates, and expiration dates may be extended as more stability data is collected. Always check Expiry Information for Pfizer COVID-19 Vaccines to obtain the most up-to-date expiration dates for the Pfizer COVID-19 vaccines you have in inventory.**

Reminders:

- **Do not use Pfizer Tris (Orange and Gray cap) products beyond 12 months from manufacture date.**
- **Expiration dates for the Pfizer Tris (Orange and Gray cap) products are NOT printed on the vaccine cartons or vials.**
- **Do not store Pfizer vials at -25°C to -15°C (-13°F to 5°F). Once vials are thawed, they should not be refrozen.**

As of 4/7/2022 Janssen COVID-19 vaccines have been granted a shelf life extension for an additional 3 months. Double check expiration dates for all Janssen lots at https://vaxcheck.jnj/ prior to wasting.

- Check the Janssen website for all lots to determine the most up to date expiration date for storage in the refrigerator
- Can be stored in the refrigerator up to **11** months (2°C and 8°C)
- Link to ADHS J&J Janssen job aid
- Link to CDC J&J Janssen web page



Vaccine Storage | **Janssen COVID-19 Vaccine**

Refrigerator

- 2.0° C to 8.0° C
- 36.0° F to 46.0° F
- Store in refrigerator for up to 11 months
- DO NOT REFREEZE

Dosage

- Each vaccine vial contains 5, 0.5mL doses to be administered
- No reconstitution required
- Discard any punctured vial held at refrigerator temperatures after 6 hours
- Discard any punctured vial held at room temperature (maximally 25°C/77°F) after 2 hours

Administration

- Standard needles and syringes
- Draw 0.5mL and inject intramuscularly (IM)
- Single dose
- For adults 18 and older
- Not for children
- Can be administered until 11:59 p.m. EST on expiry date. Expiry dates can be verified on the Janssen website

CDC Recommends Additional COVID-19 Vaccine Boosters for Certain Individuals

The CDC expanded eligibility for an additional booster dose for certain individuals who may be at higher risk of severe outcomes from COVID-19. Boosters are safe, and people over the age of 50 can now get an additional booster 4 months after their prior dose to increase their protection further.

The FDA amended the emergency use authorizations as follows:

- A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
- A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine may be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
- A second booster dose of the Moderna COVID-19 Vaccine may be administered at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with the same certain kinds of immunocompromise.

COVID-19 Vaccination Schedule for Primary and Booster Doses

COVID-19 Vaccination Schedule - for Primary Series in the General Population

Primary series vaccine manufacturer	Age Group	Number of doses in primary series	Number of booster doses	Interval between 1st and 2nd dose	Interval between primary series and booster dose
Pfizer-BioNTech Orange Cap	5-11 years	2	N/A	3 weeks	N/A
Pfizer-BioNTech Purple Cap OR Gray Cap	12 years and older	2	1*	3-8 weeks**	At least 5 months*
Moderna	18 years and older	2	1*	4-8 weeks**	At least 5 months*
Janssen	18 years and older	1	1*	NA	At least 2 months*

*All people ages 12 years and older should receive 1 booster dose of a COVID-19 vaccine. Some adults may receive a second booster dose:

- Adults ages 18-49 years: Those who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive an mRNA COVID-19 booster dose at least 4 months after the Janssen booster dose.
- Adults ages 50 years and older: A second mRNA booster dose could benefit people ages 50 years and older, as they are at increased risk for severe COVID-19. People ages 50 years and older may choose to receive a second booster dose, if it has been at least 4 months after the first booster

**An 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12 to 39 years. A shorter interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately to severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

COVID-19 Vaccination Schedule for Primary and Booster Doses

COVID-19 Vaccination Schedule - for People with Moderate or Severe Immunocompromise

Primary Vaccination	Age Group	Number of doses in primary series	Number of booster doses	Interval between 1st and 2nd dose	Interval between 2nd and 3rd dose	Interval between primary series and booster dose
Pfizer-BioNTech Orange Cap	5-11 years	3	N/A	3 weeks	At least 4 weeks	N/A
Pfizer-BioNTech Purple Cap OR Gray Cap	12 years and older	3	1*	3 weeks	At least 4 weeks	At least 3 months*
Moderna	18 years and older	3	1*	4 weeks	At least 4 weeks	At least 3 months*
Janssen	18 years and older	1 Janssen, followed by 1 mRNA	1*	4 weeks	At least 2 months	N/A*

*People ages 12 years and older may choose to receive a second booster dose using an **age-appropriate** mRNA COVID-19 vaccine if it has been at least 4 months after the first booster dose.

As of now, on March 22, 2022, the HRSA COVID-19 Uninsured Program will stop accepting claims for testing and treatment of COVID-19 due to lack of sufficient funds. On April 5, 2022, the program will also stop accepting vaccination claims due to a lack of sufficient funds. For additional information, please see the HRSA COVID-19 Uninsured Program Claims Submission Deadline FAQs and the White House Fact Sheet.

When is the final deadline to submit claims for reimbursement?

The deadlines to submit claims for each category of service are as follows:

- **Testing claims:** March 22, 2022, at 11:59 p.m. ET
- **Treatment claims:** March 22, 2022, at 11:59 p.m. ET
- **Vaccine administration claims:** April 5, 2022, at 11:59 p.m. ET

Any testing and treatment claims submitted in the Portal after March 22, 2022, will not be adjudicated for payment.

Any vaccine administration claims submitted in the Portal after April 5, 2022, will not be adjudicated for payment.

No More LIVE Brown Bag Webinar

(Our LAST live webinar was January 25th 2022)

We will continue to update these slides and post an updated copy of these slides on the COVID-19 provider resources page as needed but we will no longer hold the weekly live webinar.

ADHS COVID-19 Vaccine Website

azhealth.gov/covid19vaccine





ADHS Find Vaccine webpage azhealth.gov/findvaccine

- The locations of vaccination sites
- Filter to sort by vaccine type
- Use the patient portal at podvaccine.azdhs.gov to make an appointment for a relative
- Appointments recommended but no longer required at state-operated sites



Pandemic Provider Onboarding Start Form

- All facilities must onboard to be able to order/administer COVID-19 vaccines
- Pandemic Vaccine Provider Onboarding Tool - Job Aid (bottom right)
- Wait until you're at the facility to onboard so you can upload photos of inside and outside of units
- Read through forms for important requirements
- Note: Per the CDC Agreement, COVID-19 vaccines must be recorded in the vaccine recipient's record, the required information reported to the relevant state, local, or territorial public health authority, and decremented from the inventory **within 24 hours of administration**.



ARIZONA DEPARTMENT OF HEALTH SERVICES

Pandemic Vaccine Provider Onboard Form 1

The Arizona Immunization Program Office (AIPO) does not know if/when COVID-19 vaccines will become available. However we want to be prepared and engage our partners now, so we are ready when vaccines are available for distribution in Arizona.

Both VFC and non-VFC providers who would like to administer future COVID-19 vaccines must complete the Pandemic Provider Onboarding survey forms.

After submitting this form, you will be sent to a page with a series of subsequent survey forms. The forms serve two purposes: 1) to ensure the signatory provider knows the requirements, and 2) to ensure the facility is able to meet each requirement. The signatory provider is required to complete all of the surveys and be approved by the AIPO before this facility will be able to order future potential pandemic vaccines.

As we learn more about future vaccines we may add additional survey forms to the onboarding tool to pass the information along.

Onboarding is not an instantaneous process. It will take AIPO time to add providers to ASIIS and review requirements. Onboard now. Plan for it to take time.

The onboarding tool has the high level requirements for the signatory provider. Provider staff can go to AIPO Train to learn how to order, receive, store, administer, document, and account for pandemic vaccines in ASIIS.

We appreciate your continued efforts to help Arizonans be healthy and vaccinated.

Click the link to view the onboard Job aid to help you complete the survey forms. You are currently on Form 1.
Please contact our help desk if you have further questions: (602) 364-3899



ARIZONA DEPARTMENT OF HEALTH SERVICES

PREPARDNESS

Pandemic Vaccine Provider Onboarding Tool

How to get started

1. Click the onboarding link Pandemic Vaccine Provider Onboard Form 1 and fill out the form
2. Click submit - this will take you to survey queue page
3. Continue to complete other surveys that are not marked "Complete." A link to this page will be emailed to you

1 Contact and Shipping Information
- Facility location information
- Signatory provider info (title, license, NPI)
- Primary and backup vaccine coordinator information
- Not sure if you're a VFC/VCA provider? Select no when it asks if you are a VFC provider; this is not necessary to participate

2 Storage and Handling
- Photos of your cold storage units showing the inside of the units
- Brand and model of each cold storage unit
- Data logger usage info
- Read requirements

3 Arizona State Immunization Information System (ASIIS)
- Are you currently entering/transferring immunization data into ASIIS?
- Read requirements

4 Vaccine Planning
- Read through content so you can plan and be prepared

5 CDC Agreement Section A
- CMO & CEO signatures
- For organizations: follow the instructions for Section A in FAQs. Follow the decision tree on the final page to determine whether you need to follow organization instructions

6 CDC Agreement Section B
- Facility type
- Populations served
- Storage unit capacity
- Must be signed by the signatory provider/the primary vaccine coordinator

7 Prescribing Providers (part of CDC Agreement)
- Submit multiple times - one for each prescribing provider
- Enter each prescriber's name, title, and license number

Revised November 2020



FAQs

I clicked "Save and Return" and lost my place. What do I do?
- Find the email with the link to the survey queue page
- Click the survey queue page link
- Click on the survey you were working on
- Enter return code
- Continue survey
- If you did not save a return code, click the "start over" button to start the survey form again. You will not lose previously submitted survey forms

How will I know if I'm done?
- On the survey queue page, surveys marked "Complete" are done and surveys with a "Begin Survey" button are incomplete.

What training do I need?
- The AIPO TRAIN has training courses for staff who are responsible for daily tasks, including:
  - » How to order, receive, and account for doses in ASIIS
  - » How to use data loggers
  - » Storage & handling requirements
- Facilities are responsible for knowing and following the guidelines in the AIPO TRAIN training modules

What are the instructions for group organizations with several facility locations?
- The CDC Provider Agreement has Section A and Section B
- CMO & CEO for organizations must complete and sign Section A only once for all facility locations within the organization
- Select one facility location whose survey form will be used
- Inform the other facilities which facility location was selected
- Share the link for the survey with the CMO & CEO
- Use the "Sign and return later" button to allow both the CMO & CEO to sign the same survey form
- After the Section A survey form is signed and submitted by the CMO & CEO, a code number will be emailed to the CMO & CEO
- Have the CMO & CEO forward the email with the code number to all of the organization's facility locations
- The other facilities will enter the code number that was forwarded to them into the survey form titled "Enter code" from section A
- Complete all other sections of the CDC Agreement and onboard survey forms

NOTE: Facilities that are part of an Organization must ensure that their CMO & CEO complete a section A survey form for their Organization. No COVID-19 vaccines will be shipped to facilities whose organization has not completed/signed section A

COVID vaccinators will need to be enrolled with AHCCCS in order to be able to bill the vaccine administration fee for AHCCCS beneficiaries.
Providers can register with AHCCCS at: https://www.azahcccs.gov/PlansProviders/APEP/Access.html

Revised November 2020

Required Reporting

- ASIIS
  - for inventory accounting and dose administration data within 24 hours
    - Required even if you use an EHR, ADHS VMS app, etc.
    - Verify ASIIS Lot Number > Reconciliation page (ASIIS Inventory) numbers should be matched between the quantity on hand and physical inventory columns
      - Vaccine Inventory Management course in AIPO Train
- ArcGIS Survey 123
  - To identify every vaccination events schedule (open or closed) for GIS mapping
- Vaccines.gov/CDC VaccineFinder weekly inventory by Fridays
- Survey as needed for providers who are not using doses ordered in a timely manner
- County surveys as required by your local jurisdiction

Your ASIIS inventory is used by local, state, and federal leaders to make vaccine ordering decisions - It MUST be accurate

COVID-19 Inventory Management Reminders

In order to ensure that provider sites are being good stewards of the COVID-19 vaccines, the CDC has emphasized that each COVID-19 vaccination site should have at most 3-4 weeks of vaccine inventory on hand.

- Place smaller, more frequent orders to avoid stockpiling doses
- Use the data in ASIIS to determine how many doses you use & how many doses are on hand to place an order for an appropriate amount of doses
- Use the ADHS vaccine transfer matchmaker website to request a smaller quantity of doses then can be ordered in ASIIS
- Administered doses must be entered in ASIIS within 24 hours and decremented from the ASIIS inventory
- CDC VaccineFinder (vaccines.gov) inventory must be updated weekly by Friday
- Wasted/Expired Doses must be reported on signed and complete wasted/expired forms weekly

Off-Label Use

Pandemic providers should be aware that they must use COVID-19 vaccines according to FDA and CDC guidance. Use of COVID-19 vaccines outside of FDA and CDC recommendations (“off label”) is a violation of the provider agreement.

- Providers may not be covered under PREP Act and therefore not have the immunity from prosecution that the PREP Act provides.
- Recipients of an “off-label” COVID-19 vaccine dose may not be covered by the Countermeasure Injury Compensation Program if they were to have serious adverse events from the vaccine.
- Providers who violate the CDC agreement may not be able to remain as part of CDC programs.
- COVID-19 vaccine administration fees may not be covered if the dose were given “off-label.”

CDC Website: VFC vs. COVID-19 Vaccination Programs

- Separate programs with separate agreements
- Distinct requirements for each
- Help VFC providers understand difference between program requirements



Vaccines & Immunizations

CDC > COVID-19 Vaccination > Provider Requirements and Support

COVID-19 Vaccination
Product Info by U.S. Vaccine +
Clinical Care +
Provider Requirements and Support –
How to Enroll as a Healthcare Provider
Inventory Management Best Practices
Vaccines for Children Program vs. CDC COVID-19 Vaccination Program
Training and Education +
Vaccine Recipient Education +
Health Departments +
Planning & Partnerships +
Vaccine Effectiveness Research
Vaccination Toolkits +

Vaccines for Children Program vs. CDC COVID-19 Vaccination Program

As Emergency Use Authorization of COVID-19 vaccine products expand to include adolescents and children, it is critical to enroll providers in the COVID-19 Vaccination Program to ensure equitable access to COVID-19 vaccination services . Providers enrolled in the Vaccines for Children (VFC) program are well situated to serve in this capacity due to their direct access to the younger patient population and their familiarity with vaccine administration and federal vaccine programs. Though the VFC and COVID-19 Vaccination programs are both federal government programs, they each have distinct requirements based on the associated funding legislation. For this reason, the provider agreements remain separate, and VFC providers must sign and adhere to the requirements of the *CDC COVID-19 Vaccination Program Provider Agreement* in order to receive and administer COVID-19 vaccines. The table below has been developed to assist VFC providers in understanding the difference in the programs' requirements. **Program differences are in bold.**

	VFC Program	COVID-19 Vaccination Program
Provider Enrollment	• Providers enroll via state/local immunization program enrollment system and procedures. • **Providers must complete and sign state/local immunization program *Vaccines for Children Program Provider Agreement* and *VFC Program Provider Profile Form.***	• Providers enroll via state/local immunization program enrollment system and procedures. • **Providers must complete and sign *CDC COVID-19 Vaccination Program Provider Agreement*, Sections A and B.**
Vaccine Ordering	• Providers order routine childhood vaccines via state/local immunization program-designated ordering system and procedures.	• Providers order COVID-19 vaccines via state/local immunization program-designated ordering system and procedures. • Providers must be fully trained in vaccine

Vaccines.gov/CDC VaccineFinder Provider Resources

The "organization email" listed in Section A of the CDC Agreement will get an email from vaccinefinder@auth.castlighthealth.com to sign up

- Weekly reporting by Friday of on-hand inventory quantities is a requirement
- Activating a location to display to the public is optional
- Providers can update display to the public function at any time
- Once COVID-19 vaccine locations are launched in Vaccines.gov, changes show publicly within 24 hours
- Check phone number in provider portal before making site public
- Vaccines.gov homepage - patients can find vaccines
- NOTE: If a site that is set to display to the public fails to update inventory within 72 hours, the availability information for each vaccine will display as "Call to confirm" on Vaccines.gov.

COVID-19 Administration Reporting Systems (CARS) Help Desk

- Monday through Friday, 8:00 am to 8:00 pm ET.
- CARS_HelpDesk@cdc.gov
- 1-833-748-1979
- Provide PIN when calling



Changes to the Required Temperature Incident Reporting Process for COVID-19 Vaccine Temperature Incidents

The Arizona Immunization Program Office (AIPO) is introducing changes to the required temperature incident reporting process for COVID-19 vaccine temperature incidents. This process is intended to improve incident turnaround times for providers by allowing them to take ownership of the process by following the steps in the Temperature Incident Instructions Checklist to obtain a viability determination from the manufacturer.

This is a required process for reporting all temperature incidents involving COVID-19 vaccines. The AIPO also encourages you to please fill out the survey at the end of the process as we value your feedback.



Incident Report Checklist

AIPO

https://redcapaipo.azdhs.gov/surveys/?s=AY3C74XEPTWDXJ4H

ArizonaVFC@azdhs.gov

602.364.3642

Temperature Incident Instructions

1. Isolate the vaccines in the affected unit, label them DO NOT USE and keep them in the affected unit. Do not administer any doses exposed to out of range temperatures.

2. Download the data logger report(s) from the data logger monitoring the affected unit(s).

3. Determine how long the unit was out of appropriate temperature range and the highest and/or lowest out of range temperature documented on the data logger report.
   - If any vaccines in the affected unit have been involved in a previous temperature incident, you will need to include the time of the previous incident and the highest/lowest out of range temperature the vaccines were exposed to in your report to the manufacturer(s).

Appropriate temperature ranges:
- Refrigerator: 2.0°C to 8.0°C **OR** 36.0°F to 46.0°F
- Standard Freezer: -50.0°C to -15.0°C **OR** -58.0°F to 5.0°
- Ultra Low Temp Freezer: -130.0°F to -76.0F **OR** -90.0°C to -60.0°C

4. Create a list of all affected vaccines - include the type of vaccine, the lot numbers, the expiration dates and the manufacturers.

5. Contact each manufacturer - provide them with the information you obtained from the data logger reports (length of time vaccines were exposed to out of range temperatures and the highest and/or lowest temperature recorded), as well as affected vaccine information, and any previous incident information as requested.

6. If reporting the incident to the manufacturer via phone or through email - request a statement of viability be emailed to you by the manufacturer(s). If you are able to check the viability online with an excursion tool from the manufacturer, download a copy of the viability statement for ALL affected vaccines.

7. Report the outcome of the incident to the AIPO at this link: https://redcapaipo.azdhs.gov/surveys/?s=AY3C74XEPTWDXJ4H

Daily COVID-19 Vaccine Tasks

Temperature Monitoring

- Twice per day monitor temperatures using the approved data logger
  - Document that you monitored temperatures using the paper temp log
    - Comirnaty/Pfizer ULT Celsius Fahrenheit
    - Refrigerator Celsius Fahrenheit
    - Moderna Freezer Celsius Fahrenheit
    - Document current, min, max, time, and initials
- **If there are out of range temperatures, stop using the vaccines and submit an incident report to the AIPO**
- Twice per month download and save the data logger data reports
  - Keep the data logger reports readily available for 6 years
    Submit the data logger reports (in an acceptable file format: .xls, .txt, .ltd or .csv) to the AIPO upon request

Take a physical inventory count of doses in the cold storage units

- Compare the physical count to ASIIS lot number reconciliation inventory
- The inventories should be the exact same if doses given are entered properly in ASIIS. If you need to troubleshoot, use this job aid.
- Enter the weekly inventory by Fridays into CDC Vaccines.gov

Document doses administered in ASIIS within 24 hours

- Shipments must be marked “received” in ASIIS prior to administration in order for the doses to decrement from the inventory

If you would no longer like to participate as a pandemic provider please follow these steps

1. **Account for all doses in ASIIS**
   a. You are responsible for accounting for ALL of the doses shipped to you
   b. Ensure all doses shipped to the facility were received in ASIIS
   c. Ensure all doses administered were decremented from the ASIIS inventory
   d. ASIIS inventory reconciliation screen should be accurate
2. **If you still have doses**
   a. The doses will need to be transferred to another COVID-19 provider
   b. Transfers must have prior approval in ASIIS
3. **Enter zero in CDC Vaccines.gov inventory when your inventory is depleted**
4. **Notify ADHS *after* doses have been accounted for**

AIPO Train

- Training on ordering, receiving, and accounting for doses in ASIIS
- Information on data loggers - setting up, downloading data
- Onboarding resources
- Mass immunizations

How to Register

1. Go to https://aipo.myabsorb.com/?KeyName=PandemicProviders (This link automatically enters the enrollment key)
2. Enter required fields
3. Select Sign up
4. Click email activation link (important)

How to Log In

1. Go to https://aipo.myabsorb.com/#/login
2. Enter username and password (username will be email address)
3. Select Log In

For existing AIPO Train users: Enter enrollment key “PandemicProviders” to access pandemic-specific training

Questions? Email AIPOTrain@azdhs.gov

Administration Fee

- CMS has a toolkit to help health care providers prepare to administer vaccines
- Vaccine doses given to the American people at no cost
- Providers contractually agree to administer a COVID-19 vaccine regardless of an individual's ability to pay and regardless of their coverage status
- May not seek any reimbursement, including through balance billing, from a vaccine recipient
- People without health insurance can get COVID-19 vaccine at no cost
- If you give COVID-19 vaccines to patients who are covered by **AHCCCS** you will need to be enrolled with AHCCCS in order to bill AHCCCS the administration fee
    - Register with AHCCCS here

Facilities cannot bill patients for the cost or admin fee for COVID-19 vaccines.

CVX Code and CPT Code Resources

- CMS - Helpful for Billing
- CDC - Helpful for Uploading Data in EHR and ASIIS
- ADHS - Arizona HL7 Specific Rules

TAPI - The Arizona Partnership for Immunizations (State immunization coalition)

- COVID-19 Resources
- COVID-19 Vaccine Billing Policy Information
- Resources for immunizations at off-site locations

CDC Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

CDC has issued revised Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations to assist with jurisdictional planning and implementation of satellite, temporary, or off-site vaccination clinics by public and private vaccination organizations.

The guidance is broken down into four categories:

- Planning activities
- Pre-clinic activities
- During the clinic activities
- Post-clinic activities

The guidance also provides information on additional considerations required during the COVID-19 pandemic, including physical distancing, personal protective equipment (PPE), and enhanced sanitation efforts

Training for Healthcare Professionals

- CDC COVID-19 Vaccine Training Modules
- Public Health Foundation Training Plan





Immunization Action Coalition - immunize.org

- Info on administering vaccines
- Handouts for staff and patients
- “Ask the Experts” page
  - Includes COVID-19 vaccines
- Option to sign up for IAC Express email
  - Weekly email with updates to information and resources

CDC COVID-19 Vaccination Clinical Resources



Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States

Other resources:

- Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States
- COVID-19 Vaccine Administration Errors and Deviations



Summary Document for Interim Clinical Considerations

for Use of COVID-19 Vaccines Currently Authorized or Approved in the United States

	Pfizer-BioNTech		Moderna	Janssen
Age groups	5 through 11 years of age	12 years of age and older	18 years of age and older	18 years of age and older
Vaccine type	mRNA		mRNA	Replication-incompetent adenovirus type 26 vector
Dose	10 µg (orange cap)	30 µg (purple cap)	100 µg (primary series and additional primary dose) 50 µg (booster dose)	5×10^{10} viral particles
Dosage (volume)	0.2 mL	0.3 mL	0.5 mL (primary series and additional primary dose) 0.25 mL (booster dose)	0.5 mL
Number of doses in primary series	2		2	1
Interval between primary series doses	3 weeks (21 days)		1 month (28 days)	N/A
Additional (3rd) primary dose for moderately or severely immunocompromised persons	Currently not authorized for this age group	Recommended at least 28 days after the 2nd dose of the primary series for moderately and severely immunocompromised people 12 years of age and older (https://www.cdc.gov/vaccines/covid-19/clinical considerations/covid-19-vaccines-us.html#considerations-covid-19-vax-immunocompromised) Use the same vaccine product as the primary series See information below about a booster dose.		Not authorized as an additional primary dose. See information below about a booster dose.
Booster dose	Currently not authorized for this age group	A booster dose, at least 6 months after the last dose of a COVID-19 mRNA vaccine primary series (i.e., after the 2nd dose or the additional [3rd] dose for moderately and severely immunocompromised persons): • Should be given to persons 18 years of age and older (Use of heterologous – mix and match – booster doses is allowed) • May be given to persons 16 and 17 years of age based on individual benefits and risks	A booster dose, at least 6 months after the last dose of a COVID-19 mRNA vaccine primary series (i.e., after the 2nd dose or the additional [3rd] dose for moderately and severely immunocompromised persons): • Should be given to persons 18 years of age and older (Use of heterologous – mix and match – booster doses is allowed)	A booster dose, at least 2 months (8 weeks) after the primary Janssen single dose:Use of heterologous (mix and match) booster doses is allowed. • Should be given to all persons who 18 years of age an older (Use of heterologous - mix and match - booster doses is allowed) • A moderately or severely immunocompromised person who received a primary Janssen COVID-19 Vaccine should not receive more than 1 booster dose (total of 2 doses).
		For additional information, see Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in theUnited States https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-covid19-vax-immunocopromised		
Interval between primary and booster doses	n/a	At least 6 calendar months after completing the primary series or additional primary dose (for moderately or severely immunocompromised)	At least 6 calendar months after receiving the primary series or additional primary dose (for moderately or severely immunocompromised)	At least 2 months (8 weeks) after receiving the primary dose

CDC Vaccine Storage and Handling Toolkit

Get Email Updates

To receive email updates about this page, enter your email address:

Email Address

What's this? Submit

Related Links

Vaccines & Immunizations

View or Print Toolkit

The Vaccine Storage and Handling Toolkit is a comprehensive guide that reflects best practices for vaccine storage and handling from Advisory Committee on Immunization Practices (ACIP) recommendations, product information from vaccine manufacturers, and scientific studies.

Vaccine Storage and Handling Resources

Access additional resources including web-based trainings, videos, checklists, and references related to vaccine storage and handling.

These example vaccine labels can be used to organize vaccines within the storage unit. Referenced in the storage and handling toolkit.

- 2020-2021 Influenza Season Vaccine Label Examples [4 pages] (Sept 2020)
- Vaccine Labels Examples [20 pages] (Jan 2021)



View, download, and print the 2021 Vaccine Storage and Handling Toolkit.

More

Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites

- Emergency equipment that should be immediately available
- Routine observation periods following COVID-19 vaccination
- Early recognition of anaphylaxis
- Management of anaphylaxis at a COVID-19 vaccination location
- Considerations for anaphylaxis management in special populations
- Patient counseling
- Reporting anaphylaxis

Locations administering COVID-19 vaccines should adhere to CDC guidance, including screening recipients for contraindications and precautions, having necessary supplies and staff members available to manage anaphylaxis, implementing recommended post vaccination observation periods, and immediately treating suspected anaphylaxis with intramuscular epinephrine injection.

CDC v-safe system

- Give patients a **v-safe** information sheet at the time of vaccination
- Suggested healthcare provider script**:** *CDC has created a way for you to report how you feel after COVID-19 vaccination through a smartphone-based tool that uses text messaging and web surveys to check in with you. Here (or in your packet) is a **v-safe** information sheet with more details and simple instructions to sign up.*
- Parents and guardians can now enroll adolescents (ages 5 and older) in the v-safe after vaccination health checker℠ and complete health check-ins on their behalf after COVID-19 vaccination.
- Poster and website translated into multiple languages

Get vaccinated.
Get your smartphone.
Get started with v-safe.

What is v-safe?

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. Through ***v-safe***, you can quickly tell CDC if you have any side effects after getting the COVID-19 vaccine. Depending on your answers, someone from CDC may call to check on you. And ***v-safe*** will remind you to get your second COVID-19 vaccine dose if you need one.

Your participation in CDC's ***v-safe*** makes a difference—it helps keep COVID-19 vaccines safe.

How can I participate?

Once you get a COVID-19 vaccine, you can enroll in ***v-safe*** using your smartphone. Participation is voluntary and you can opt out at any time. You will receive text messages from ***v-safe*** around 2pm local time. To opt out, simply text "STOP" when ***v-safe*** sends you a text message. You can also start ***v-safe*** again by texting "START."

How long do v-safe check-ins last?

During the first week after you get your vaccine, ***v-safe*** will send you a text message each day to ask how you are doing. Then you will get check-in messages once a week for up to 5 weeks. The questions ***v-safe*** asks should take less than 5 minutes to answer. If you need a second dose of vaccine, ***v-safe*** will provide a new 6-week check-in process so you can share your second-dose vaccine experience as well. You'll also receive check-ins 3, 6, and 12 months after your final dose of vaccine.

Is my health information safe?

Yes. Your personal information in ***v-safe*** is protected so that it stays confidential and private.*

*To the extent ***v-safe*** uses existing information systems managed by CDC, FDA, and other federal agencies, the systems employ strict security measures appropriate for the data's level of sensitivity. These measures comply, where applicable, with the following federal laws, including the Privacy Act of 1974; standards enacted that are consistent with the Health Insurance Portability and Accountability Act of 1996 (HIPAA); the Federal Information Security Management Act, and the Freedom of Information Act.

12/01/20

v-safe℠
after vaccination health checker

Use your smartphone to tell CDC about any side effects after getting the COVID-19 vaccine. You'll also get reminders if you need a second vaccine dose.

Sign up with your smartphone's browser at

OR

Aim your smartphone's camera at this code

VAERS Reporting and Safety Info - vaers.hhs.gov

VAERS accepts all reports from everyone regardless of the plausibility of the vaccine causing the event or the clinical seriousness of the event.



ADHS Vaccine Reference Sheets

Comirnaty/Pfizer Gray Cap (Age 12+)
- Comirnaty/Pfizer Vaccine Reference Sheet

Comirnaty/Pfizer Purple Cap (Age 12+)
- Comirnaty/Pfizer Vaccine Reference Sheet
- ADHS Dry Ice Handling/Recharge Flyer

Pfizer Orange Cap (Age 5-11)
- PEDIATRIC Pfizer Vaccine Reference Sheet

Moderna (Age 18+)
- Moderna Vaccine Reference Sheet
  - Wastage Reporting Table

Janssen (Age 18+)
- Janssen Vaccine Reference Sheet
- What Patients and Providers Need to Know About the Janssen Vaccine



EUA Fact Sheets

Routine vaccines are given with a Vaccine Information Statement (VIS)
COVID-19 vaccines under the Emergency Use Authorization (EUA) will be given with an EUA Factsheet.

- Comirnaty/Pfizer Fact Sheet
- Comirnaty and Pfizer EUA fact sheet translated in other languages
  - Includes Pediatric Pfizer (Age 5-11) fact sheets
- Moderna Fact sheet
- Moderna EUA fact sheet translated in other languages
- Janssen Fact Sheet
- Janssen EUA fact sheet translated in other languages

COVID-19 Vaccine Presentations Job Aid

***Pfizer-BioNTech (Ages 12+) - Purple Cap 1170 is no longer available to order in ASIIS.**

Pfizer-BioNTech (Ages 12+, NO diluent) - Gray Cap is now available to order in ASIIS.

300-dose minimum order

- 6 dose multi-dose vials (0.3mL)
- Shipped in a single use thermal shipping container, DO NOT return
- Controlant data logger included in shipment must be returned

ARIZONA DEPARTMENT OF HEALTH SERVICES

COVID-19 Vaccine Presentations Available to Order in ASIIS

Pfizer-BioNTech (Ages 12+, No Diluent) - Gray Cap

300-dose minimum order

- 6-dose multi-dose vial (0.3 mL)
- Shipped in a single use thermal shipping container, DO NOT return
- Controlant data logger included in shipment must be returned
- NDC 59267-1025-04

Pediatric Pfizer-BioNTech (Ages 5-11) - Orange Cap

100-dose minimum order

- 10-dose multi-dose vial (0.2 mL)
- Shipped in a single use thermal shipping container, DO NOT return
- Controlant data logger included in shipment must be returned
- NDC 59267-1055-04

Moderna (Ages 18+)

100-Dose Minimum Order

- 10-dose multi-dose vial (range: 10–11 doses) (0.5 mL)
- NDC 80777-0273-99



Janssen (Ages 18+)

100-Dose Minimum Order

- 5-dose multi-dose vial (0.5 mL)
- NDC 59676-0580-15

UPDATED 12/21/2021

FDA gives Moderna COVID-19 vaccine full approval for use in ages 18 and older

- The Food and Drug Administration (FDA) has given full approval to the Moderna COVID-19 vaccine for use in those ages 18 and older.

- Moderna joins the Pfizer-BioNTech vaccine, which the FDA gave full approval to last August for use in ages 16 and older. Ages 5 to 15 are eligible for the Pfizer COVID-19 vaccine under an FDA emergency use authorization.

Moderna Label Update

FDA recently approved updates to both label and the EUA fact sheet for the Moderna COVID-19 vaccine. Distribution of the Moderna vials with the updated labels (see new label above) began during the week of January 13, 2021.

What has changed on the label of the Moderna COVID-19 vaccine:

- The label has been updated to indicate a volume of 5.5mL.
- Doses for primary series and booster shots are now listed on the label.
- Important reminder not to exceed a maximum of 20 punctures per vial



What remains the same for the Moderna COVID-19 vaccine:

- Formulation
- NDC
- Physical vial size
- Number of reportable doses
- Dose volumes (See Below)
- Reporting requirements
    - Wastage should continue to be reported based on 10 doses per vial.
- Proper dosage of Moderna COVID-19 Vaccine
    - Primary series doses 1 and 2 dosage = 0.5 mL
    - Additional primary dose (3rd) dosage for immunocompromised persons = 0.5 mL
    - Booster dosage = 0.25 mL
- Each vial can ONLY be punctured up to 20 times.
    - Once the vial has reached the 20-puncture limit, the vial should be discarded **even if there is vaccine remaining in the vial**.

For more information, please refer to the EUA fact sheet or Administration Overview for Moderna COVID-19 Vaccine | CDC.

Moderna Booster Reporting of Administered and Wasted Doses

- Quick rule of thumb: As long as the vial has been punctured 10 or 14 times and 10 or 14 doses were administered (regardless if they were full primary series doses or half booster doses) there will be no reported wastage.
- Example from the 14 dose vial table: 5 full doses (primary series) were administered and 5 half doses (booster doses) were administered before the 12 hour limit was reached. 4 doses should now be reported as wastage.



Moderna 10 Dose Vial Wastage Table

Half Doses \ Full doses	0	1	2	3	4	5	6	7	8	9	10
0	10	9	8	7	6	5	4	3	2	1	0
1	9	8	7	6	5	4	3	2	1	0	
2	8	7	6	5	4	3	2	1	0		
3	7	6	5	4	3	2	1	0			
4	6	5	4	3	2	1	0				
5	5	4	3	2	1	0					
6	4	3	2	1	0						
7	3	2	1	0							
8	2	1	0								
9	1	0									
10	0										
11											
12											
13											
14											
15											
16											
17											
18											
19											
20											

Green Area = No Wa

Moderna 14 Dose Vial Wastage Table

Half Doses \ Full doses	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
0	14	13	12	11	10	9	8	7	6	5	4	3	2	1	0
1	13	12	11	10	9	8	7	6	5	4	3	2	1	0	
2	12	11	10	9	8	7	6	5	4	3	2	1	0		
3	11	10	9	8	7	6	5	4	3	2	1	0			
4	10	9	8	7	6	5	4	3	2	1	0				
5	9	8	7	6	5	4	3	2	1	0					
6	8	7	6	5	4	3	2	1	0						
7	7	6	5	4	3	2	1	0							
8	6	5	4	3	2	1	0								
9	5	4	3	2	1	0									
10	4	3	2	1	0										
11	3	2	1	0											
12	2	1	0												
13	1	0													
14	0														
15															
16															
17															
18															
19															
20															

No Waste Reported

Green Area = No Waste Reported

Moderna Puncture Tracking Log

- Keep track of how many times vials have been punctured
- Vials can only be punctured maximum of 20 times
- Mark half-doses vs full doses
- Can track 2 vials per log



Moderna Puncture Tracking Log

Vial Lot #:_____
Start Time: End Time:

Dose	Full (0.5 mL)	Half (0.25 mL)
1	☐	☐
2	☐	☐
3	☐	☐
4	☐	☐
5	☐	☐
6	☐	☐
7	☐	☐
8	☐	☐
9	☐	☐
10	☐	☐
11	☐	☐
12	☐	☐
13	☐	☐
14	☐	☐
15	☐	☐
16	☐	☐
17	☐	☐
18	☐	☐
19	☐	☐
20	☐	☐

Vial Lot #:_____
Start Time: End Time:

Dose	Full (0.5 mL)	Half (0.25 mL)
1	☐	☐
2	☐	☐
3	☐	☐
4	☐	☐
5	☐	☐
6	☐	☐
7	☐	☐
8	☐	☐
9	☐	☐
10	☐	☐
11	☐	☐
12	☐	☐
13	☐	☐
14	☐	☐
15	☐	☐
16	☐	☐
17	☐	☐
18	☐	☐
19	☐	☐
20	☐	☐

Reminders

- Moderna booster doses are 0.25mL (half the dose size of a primary series dose)
- Moderna vials can only be punctured a maximum of 20 times
- Providers are responsible to keep track of the number of punctures for each vial
- Punctured Moderna vials can be used to administer both primary and booster doses
- Punctured Moderna vials must be used within 12 hours

602-364-3899
ArizonaVFC@azdhs.gov
azdhs.gov/covid19/vaccines

Updated 12/2021

Pediatric Pfizer (Age 5-11) COVID-19 Vaccine Authorized

- The Pfizer COVID-19 Vaccine is over 90% effective at preventing COVID-19 in children ages 5 through 11 years.
- COVID-19 vaccines have undergone—and continue to undergo—the most intensive safety monitoring in U.S. history. In clinical trials of about 3,000 children, serious side effects were rare and self-limiting.
- After getting a COVID-19 vaccine, children may have some side effects similar to those seen in adults and with other vaccines which is normal.
- This recommendation was made based on in-depth review of available safety, immunogenicity, and efficacy data.
- Pediatric COVID-19 vaccines will be available at no cost.

You can only puncture the diluent once

Orders of Pfizer age 5-11 vaccine include ancillary kits that contain 10mL diluent vials. While these vials appear to contain sufficient diluent for multiple vials, they must only be used once.

- Diluent vials are a one-time-use item and should be discarded with the remaining content after each use.
- For each vial of vaccine, extract 1.3mL of diluent from a single-use vial to reconstitute 1.3mL of vaccine
- Do not be tempted to puncture diluent vials more than once.

Pfizer pediatric doses (5-11) should NOT be reported as adult doses

Reminder:

The CPT and CVX codes for the Pfizer age 5-11 vaccine and the Pfizer age 12+ vaccine are different.

Please ensure that your EHR has been updated to document the vaccines correctly.

For information on Arizona HL7 Specific Rules for Version 2.5.1, click here.

For information on List of Vaccine Names, Best ASIIS Selection and CPT/CVX Codes, click here.



List of Vaccine Names, Best ASIIS Selection and CPT/CVX Codes

ARIZONA DEPARTMENT OF HEALTH SERVICES

This list matches the vaccine name or codes in Arizona State Immunization Information System (ASIIS) with the brand name or other common names of the vaccines you use most often.

Vaccine trade name or common name	Fund	Best ASIIS Selection	Age (Range)	Dose	Route	Manufacturer/ NDC Number	CPT Code	CVX Code
COVID-19 Vaccines								
COMIRNATY Pfizer COVID-19 Vaccine	PAN	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose	16+ years 12+ years EUA	0.3 ml	IM	Pfizer, INC – PFR NDC: 59267-1000-02 (195pack-6dose vials) (1170 doses)	91300	208
	PAN	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	5-<12 years EUA	0.2 ml	IM	Pfizer, INC – PFR NDC: 59267-1055-04 (10pack-10dose vials) (100 doses)	91307	218
Moderna COVID-19 Vaccine	PAN	COVID-19, mRNA, LNP-S, PF,	18+ years	0.5 ml	IM	Moderna – MOD NDC: 80777-0273-99 (10pack-10dose vials) (100 doses)	91301	207
Janssen COVID							91303	212
AstraZeneca COVID-							91302	210
Novavax COVID-19								211
Sinopharm (BIBP) C								510
Coronavac (Sinovac								511
SARS-COV-2 (COVID								213

Arizona HL7 Specific Rules for Version 2.5.1

The following specifications and rules supersede CDC and general HL7 guidelines when sending messages to the Arizona Immunization Program. Otherwise CDC and general HL7 guidelines apply.

MSH.1 – **Field Separator** will be the pipe **|** identified as (ASCII 24)

MSH.2 – **Encoding Characters** will be **^~\&** identified as (ASCII 94, ASCII 126, ASCII 92, ASCII 38) respectively.

MSH.3 – **Sending Application** is **required**

MSH.4 – **Sending Facility** is **required** and shall be the **IRMS ID** assigned and provided by the ASIIS System.

MSH.5 – **Receiving Application** is **required** and shall always be **ASIIS**.

MSH.6 – **Receiving Facility** is **required** and shall always be **ASIIS**.

MSH.7 – **Date/Time of Message** is **required** and shall be in the following format (**YYYYMMDDHHMMSS**) and have a degree of precision to the minute generated.

MSH.9 – **Message Type** is **required** and shall be **VXU^V04^VXU_V04** for Unsolicited Vaccination Messages.

MSH.10 – **Message Control ID** is **required** and shall be unique for each message attempt from a sending facility with a maximum of 20 characters.

MSH.11 – **Processing ID** is **required** and because the ASIIS system has separate points for

Pediatric Pfizer Gray Cap (12+) Job Aid

- ***NEW*** **Can be stored in ULT freezers for up to 12 months**
- Can be refrigerated for up to 10 weeks
- DO NOT use thermal shipping container or standard freezer for storage
- 6-dose vial
- ***DO NOT*** *dilute prior to use*
- DO NOT keep vaccine at room temperature for longer than 12 hours
- Discard vial 12 hours after first puncture



Pfizer-BioNTech's COVID-19 Gray Cap) Ages 12+

Vaccine Storage

Pfizer-BioNTech's COVID-19 Vaccine (Gray Cap) Ages 12+

Ultra-Cold Temperature Freezer

- -90.0°C to -60.0°C
- Can be stored for 9 months at ultra low temps

DO NOT DILUTE

Thermal Shipping Container (DO NOT USE FOR STORAGE)

- Pfizer-BioNTech's COVID-19 Vaccine (Gray Cap) CANNOT be stored in the thermal shipping container

Freezer (DO NOT USE FOR STORAGE)

- The Pfizer-BioNTech's COVID-19 Vaccine (Gray Cap) CANNOT be stored In the freezer

Refrigerator

- 2.0°C to 8.0°C
- Store vaccine vials for up to 10 weeks

ARIZONA DEPARTMENT OF HEALTH SERVICES
PREPAREDNESS

Disclaimer: Subject to change due to FDA EUA approval
UPDATED 12/21/2021

reezer:
l ready
3 hours
es before
0 weeks)
for longer than 12 hours
ularly (IM) in the deltoid
tion (Gray Cap) to children
the number of doses per vial after
ial labels and cartons.
Subject to change due to FDA EUA approval
UPDATED 12/21/2021

Pediatric Pfizer Orange Cap (Ages 5-11) Manufacturing Date vs Expiration Date

- Date printed on vial and tray is **manufacturing date only**
- Base expiration date on storage method and manufacturing date. For example:
  - If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
  - If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.
- Use Pfizer Age 5-11 EUA Fact Sheet (Page 3)
- Use Pfizer website

Pediatric Pfizer Orange Cap (Ages 5-11) Shippers

- Shipper CANNOT be used for temp storage
- Can only be stored in ULT freezers and refrigerators
- Shipper does not need to be returned
- Controlant data logger **does** need to be returned

Pediatric Pfizer Orange Cap (Ages 5-11) Job Aid

- ***NEW*** **Can be stored in ULT freezers for up to 12 months**
- Can be refrigerated for up to 10 weeks
- DO NOT use thermal shipping container or standard freezer for storage
- 10-dose vial
- Draw 0.2mL of diluted vaccine
- Discard 12 hours after dilution



Pfizer Purple Cap (Age 12+) Job Aid

Vaccine Storage

Pfizer-BioNTech's COVID-19 Vaccine (Purple Cap) Ages 12+

Ultra-Cold Temperature Freezer

- -90.0°C to -60.0°C
- Can be stored for 9 months at ultra low temps

Thermal Shipping Container with Dry Ice Pellets

- Will maintain -90.0°C to -60.0°C for up to 30 days upon re-icing
- Up to 6 recharges (re-icings) are authorized
- 1st recharge (re-icing) within 24 hours of receipt and upon opening the thermal shipper
- Dry ice recharges will NOT be provided for any configurations
- Re-icings required every 5 days after the 1st re-icing to maintain temperature
- May only be opened up to 2 times per day (≤ 3 minutes per opening)

Freezer

- -25.0°C to -15.0°C
- Store for up to 2 weeks
- May be returned one time to the recommended storage condition of -90.0°C to -60.0°C

Refrigerator

- 2.0°C to 8.0°C

Pfizer-BioNTech's COVID-19 Vaccine (Purple Cap) Ages 12+

Thawing

- When removing from ultra-cold temperature:
- Thaw at 2.0°C to 8.0°C for 3 hours OR Thaw at room temperature for 30 minutes
- If unable to dilute, store thawed undiluted vials at 2.0°C to 8.0°C (up to 1 month)
- DO NOT open vial trays or remove vials until ready for thawing or use

Vaccine and Diluent

- Use 1 vial for every 6 recipients (6-dose vial)
- Dilute a single thawed vial with 1.8mL of 0.9% Sodium Chloride Injection, USP (supplied with ancillary kit)
- DO NOT USE ANY OTHER DILUENT
- DO NOT shake vial upon dilution
- Gently mix by turning vial over and back 10 times
- Must use diluted vaccine within 6 hours
- Discard any unused, diluted vaccine after 6 hours

Administration

- Draw 0.3mL of diluted vaccine and inject intramuscularly (IM) in the deltoid muscle
- Second dose due a minimum of 21 days later
- Full FDA Approval for ages 16+
- FDA EUA approval still for ages 12-15 years
- Pregnant/lactating women can choose to be vaccinated - talk with your healthcare provider
- DO NOT administer the Pfizer adult formulation (purple cap) to children

COVID-19 Vaccine Transfer Matchmaker Tool

- **Share vaccine with other active COVID-19 providers**
- Request vaccine from nearby locations if active providers need vaccine
- You can transfer needles as well
- Only serves as connection between providers
- **All transfers must still have prior approval in ASIIS, must follow all transfer steps**
- Matchmaker Tool Job Aid
  - Transfer steps
  - Helpful resources linked



ACIP Recommends 3rd Dose for Immunocompromised

- People who have undergone solid organ transplantation or have been diagnosed with conditions that are considered to have an equivalent level of immunocompromise
- Additional dose should optimally be the same mRNA vaccine as the primary series
- If that brand is not available, the other brand of mRNA COVID-19 vaccine can be used
- Additional dose should be administered 28+ days after primary mRNA COVID-19 vaccine series
- Does not apply to individuals who received Janssen COVID-19 as a primary series
- Web page for consumers
- Web page for healthcare providers
- **Please diligently screen patients and check patients' vaccination history in ASIIS**
- If you discover 3rd dose was inadvertently administered:
    - Review CDC COVID-19 Administration Errors and Deviations

ADHS Consent Form Template

- No Federal requirement for informed consent relating to immunization
- Available for providers who do not have own consent form
- Use with CDC Pre-Vaccination checklist
- Spanish ADHS consent form
- Spanish CDC Pre-Vaccination Checklist



Prevaccination Checklist for COVID-19 Vaccines

CDC

For vaccine recipients:

Patient Name _____

The following questions will help us determine if there is any reason you should not get the COVID-19 vaccine today.

Age _____

If you answer "yes" to any question, it does not necessarily mean you should not be vaccinated. It just means additional questions may be asked. If a question is not clear, please ask your healthcare provider to explain it.

	Yes	No	Don't know
1. Are you feeling sick today?			
2. Have you ever received a dose of COVID-19 vaccine?			
• If yes, which vaccine product did you receive? ☐ Pfizer ☐ Moderna ☐ Janssen (Johnson & Johnson) ☐ Another product _____			
3. Have you ever had an allergic reaction to: (This would include a severe allergic reaction [e.g., anaphylaxis] that required treatment with epinephrine or EpiPen® or that caused you to go to the hospital. It would also include an allergic reaction that occurred within 4 hours that caused hives, swelling, or respiratory distress, including wheezing.)			



ADHS COVID-19 Vaccine Consent Form

ARIZONA DEPARTMENT OF HEALTH SERVICES PREPAREDNESS

Use this form in conjunction with the CDC Pre-Vaccination Checklist for COVID-19 Vaccines.

(Staff only) Appointment ID: _____

Patient Information

Last Name | First Name | Middle Name (optional)

Mother's Maiden Name (Optional) | Date of Birth (MM/DD/YYYY) | Gender

Address | Apartment Number | City | State | Zip

◯ No address available

Phone Number

Email Address

Insurance Information

Do you have insurance? ◯ Yes ◯ No

Plan Name | Plan Group ID # | Plan Individual ID #

Name of Person Covered By Plan | Plan Responsible Person Name

Private Insurance Address and Phone Number (If Available)

CONSENT AND ASSIGNMENT OF BENEFITS: *I have had a copy of the Emergency Use Authorization for the COVID-19 vaccine made available to me. I have had a chance to ask questions and I believe I understand the benefits and risks of the COVID-19 vaccines requested. I ask that the vaccines be administered to me or the person for whom I am authorized to make this request.*

I certify that I am: (1) the patient and at least 18 years of age; (2) the legal guardian of the patient and the patient's age makes him/her eligible to receive the vaccine based on the current emergency use authorization; or (3) a person authorized to consent on behalf of the patient where the patient is unable to consent for themselves.

I hereby assign to _____ any insurance or other third-party benefits available for the administration fee of the COVID-19 vaccine provided to me. I agree to forward to _____ all health insurance and other third-party payments I receive for services rendered to me immediately upon receipt.

I agree to allow the health care provider to release information to the Arizona State Immunization Information System (ASIIS) to record that I (or for the person for whom I am authorized to consent) have received this COVID-19 vaccine. This information will help keep track of the manufacturer and doses of the vaccine.

Patient Printed Name | Patient Signature | Date Signed

Parent/Guardian/Authorized Person Printed Name | Authorized Person's Signature | Date Signed

Vaccine Administration Information for Immunizer Use Only

Administration Date | Manufacturer | NDC # | ◯ LEFT ARM ◯ RIGHT ARM

Lot Number | Expiration Date | Route | Site

Administering Immunizer Name and Title | Administering Immunizer Signature

Is this the patient's first, second, or third dose? ◯ First ◯ Second ◯ Third ◯ Booster Dose

ADHS Does Not Provide Exemption Forms for Adults for the COVID-19 Vaccine

- Individual facilities and employers may choose to set their own immunization requirements for adults
- If an employer is requiring a COVID-19 Vaccine for their employees, and the employee is refusing vaccination, direct that patient to their Human Resources department
- Adults who have questions on immunization exemptions, for any vaccine, should contact the facility or employer who has set the requirement

Standing Order Links

[Link to Moderna](#)

[Link to Pfizer](#)

[Link to Janssen](#)



Moderna COVID-19 Vaccine

Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older

Vaccine	Dosage (amount)/ Route
Moderna-Primary Series	**0.5 mL**/IM injection
Moderna-Booster Dose	**0.25mL**/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess persons 18 years of age and older for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

- Primary-series vaccination
  - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
  - If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, administer the second dose at an interval of least 28 days.
  - If the vaccine product given as the first dose cannot be determined or is no longer available, any mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.
  - If 2 doses of an mRNA vaccine or a single dose of Janssen COVID-19 Vaccine has been administered, the person is considered fully vaccinated 2 weeks after completing the primary vaccination series.
- Persons with a history of myocarditis or pericarditis:
  - If history is prior to COVID-19 vaccination may receive any FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis has completely resolved
  - If myocarditis or pericarditis occurs after a dose of an mRNA vaccine, do not administer a subsequent dose of vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-pfizer-biontech-moderna
  - Inform recipients, especially males 12 through 29 years of age and their parents/legal representative (when relevant) of the possibility of myocarditis or pericarditis following receipt of mRNA COVID-19 vaccines and the need to seek care if symptoms of myocarditis or pericarditis develop after vaccination.*
- Additional primary dose for persons who are moderately or severely immune compromised†
  - For a person aged 18 years and older who received a Moderna primary mRNA vaccine series: Administer an additional primary dose of Moderna vaccine at least 28 days after an initial 2-dose Moderna primary series. If the vaccine product cannot be determined or is no longer available, administer either mRNA COVID-19 product.
- Persons who have received HCT or CAR-T-cell therapy
  - Revaccinate persons who received doses of COVID-19 vaccine prior to receiving HCT or CAR-t-cell therapy with a primary series at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.
- Booster doses
  - Administer a booster dose, at least 6 months after the last dose of a COVID-19 mRNA vaccine primary series (i.e., the 2nd dose or additional primary series dose for moderately or severely immunocompromised persons) to persons 18 years of age and older.
  - Persons previously vaccinated with Janssen COVID-19 Vaccine: Administer a booster dose at least 2 months after the Janssen COVID-19 Vaccine primary series.
  - Use of heterologous booster doses is allowed. Any FDA-approved or FDA-authorized COVID-19 vaccine product can be administered.
  - For additional information, see Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-



FORMULATION: 12 Years of Age and Older

Pfizer-BioNTech COVID-19 Vaccine

Standing Orders for Administering Vaccine

Vaccine	Diluent	Dosage (amount)/ Route
Formulation: **12 years of age and older** (purple cap)	**1.8 mL** of 0.9% sodium chloride (normal saline, preservative-free) diluent	**0.3 mL**/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess persons 12 years of age and older for vaccination with Pfizer BioNTech COVID-19 Vaccine based on the following criteria:

- Primary-series vaccination
  - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Pfizer-BioNTech COVID-19 vaccine.
  - If the recipient has received 1 previous dose of Pfizer-BioNTech COVID-19 Vaccine, administer the second dose at an interval of least 21 days.
  - If the vaccine product given as the first dose cannot be determined or is no longer available, any mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.
  - If 2 doses of an mRNA vaccine or a single dose of Janssen COVID-19 Vaccine has been administered, the person is considered fully vaccinated 2 weeks after completing the primary vaccination series.
- Persons with a history of myocarditis or pericarditis:
  - If history is prior to COVID-19 vaccination may receive any FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis has completely resolved
  - If myocarditis or pericarditis occurs after a dose of an team. Considerations can be found at https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-pfizer-biontech-moderna
  - Inform recipients, especially males 12 through 29 years of age and their parents/legal representative (when relevant) of the possibility of myocarditis or pericarditis following receipt of mRNA COVID-19 vaccines and the need to seek care if symptoms of myocarditis or pericarditis develop after vaccination.*
- Additional primary dose for persons who are moderately or severely immune compromised†
  - For a person aged 12 years and older who received a Pfizer-BioNTech primary mRNA vaccine series: Administer an additional primary dose of Pfizer-BioNTech vaccine at least 28 days after an initial 2-dose Pfizer-BioNTech primary series. If the vaccine product cannot be determined or is no longer available, administer either mRNA COVID-19 product.
- Persons who have received HCT or CAR-T-cell therapy
  - Revaccinate persons who received doses of COVID-19 vaccine prior to receiving HCT or CAR-T-cell therapy with a primary series at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.
- Booster doses
  - A booster dose, at least 6 calendar months after the last dose of a COVID-19 mRNA vaccine primary series (i.e., after the 2nd dose or the additional [3rd] dose for moderately or severely immunocompromised persons)
    - Should be administered to persons 18 years of age and older (Use of heterologous – mix and match – booster doses is allowed)
    - May be administered to persons 16 and 17 years of age based on their individual benefits and risks
- Additional Clinical Considerations
  - For persons who received a COVID-19 vaccine:
    - Outside of the United States



Janssen COVID-19 Vaccine (Johnson & Johnson)

Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older

Vaccine	Dosage (amount)/ Route
Janssen COVID-19 Vaccine (Johnson & Johnson)	**0.5 mL**/IM injection

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess persons 18 years of age and older for vaccination with Janssen COVID-19 Vaccine based on the following criteria:

- If the recipient has never received a COVID-19 vaccine, administer 1 dose of Janssen COVID-19 vaccine.
- If the recipient has received 1 dose of a Janssen COVID-19 Vaccine, no additional primary-series doses are needed. A booster dose is recommended 2 months (8 weeks) after the primary Janssen dose; any FDA-authorized or approved COVID-19 vaccine may be given.
- If 2 doses of an mRNA vaccine or a single dose of Janssen COVID-19 Vaccine has been administered, the person is considered fully vaccinated 2 weeks after completing the primary vaccination series.
- In situations where the first dose of an mRNA COVID-19 vaccine was received but the patient is unable to complete the series with either the same or different mRNA COVID-19 vaccine, (e.g., due to contraindication) consideration may be given to vaccination with the Janssen COVID-19 Vaccine at a minimum interval of 28 days after receipt of mRNA COVID-19 vaccine dose. However, vaccination should be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions. Consider referral to an allergist-immunologist.*
- Thrombocytopenia syndrome (TTS) and thrombocytopenia:
  - Inform women aged 18-49 years of the increased risk of thrombosis with thrombocytopenia syndrome (TTS) in their age group after Janssen COVID-19 vaccination and about the availability of other authorized vaccines (i.e., mRNA vaccines).
  - A second dose of Janssen COVID-19 vaccine is not recommended for people who had TTS after their first dose. These people may receive a dose of mRNA COVID-19 vaccine as a booster dose at least 2 months (8 weeks) after their dose of Janssen vaccine and after their clinical condition has stabilized.†
    - A consultation with the patient's clinical team, including hematologists or other specialists, should be considered.
  - Offer another FDA-authorized or approved vaccine (i.e., mRNA vaccine) to unvaccinated persons with a history of an episode of an immune-mediated syndrome characterized by thrombosis and thrombocytopenia (e.g., heparin-induced thrombocytopenia) if it has been 90 days or less since their illness resolved. After 90 days, patients may be vaccinated with any FDA-authorized or approved COVID-19 vaccine.

NOTE: Persons at risk or with a history of other thrombosis not associated with thrombocytopenia can receive an FDA-authorized or approved vaccine

- People with a history of Guillain-Barré Syndrome (GBS):
  - Can receive any FDA-authorized or approved COVID-19 vaccine. However, given the possible association between the Janssen COVID-19 Vaccine and an increased risk of GBS, discuss with these patients the availability of mRNA COVID-19 vaccines that offer protection against COVID-19.
- Persons who have received HCT or CAR-T-cell therapy
  - Revaccinate persons who received doses of COVID-19 vaccine prior to receiving HCT or CAR-T-cell therapy with a primary series at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.
- Booster doses:
  - Administer a booster dose at least 2 months (8 weeks) after completion of the Janssen COVID-19 Vaccine primary dose to:

Vaccine Manufacturer COVID-19 Websites

- Comirnaty/Pfizer COVID-19 Website
- Moderna COVID-19 Website
- Janssen COVID-19 Website







CDC COVID-19 Vaccine Resources

- [CDC Pfizer (Comirnaty) Resource Page]
- [CDC Moderna Resource Page]
- [CDC Janssen Resource Page]

Janssen COVID-19 Vaccine (Johnson & Johnson)
Vaccine Preparation and Administration Summary

General Information
Vaccine: Janssen COVID-19 Vaccine (Johnson & Johnson)

Administration
Intramuscular (IM) injection in the deltoid muscle

Moderna COVID-19 Vaccine
Vaccine Preparation and Administration Summary

General Information
Vaccine: Moderna COVID-19 Vaccine

Thawing Frozen Vaccine
- Frozen vaccine must be thawed before using.
- Thaw vaccine in the refrigerator or at room temperature:
  - **Refrigerator:** Between 2°C and 8°C (36°F and 46°F). Unpunctured vials may be stored in the refrigerator for up to 30 days.
  - **Room temperature:** Between 8°C and 25°C (46°F and 77°F). Unpunctured vials may be held at room temperature for up to 24 hours.
- Amount of time needed to thaw vaccine varies based on temperature and number of vials.
  - In the refrigerator: Up to 3 hours
  - Room temperature: Up to 1 hour and 30 minutes
- **Do NOT** refreeze thawed vaccine.
- Use vials in the refrigerator before removing vials from the freezer.
- Use CDC's beyond-use date labels for this vaccine to track storage time at refrigerated temperatures.

Expiration Date
To determine the expiration date, scan the QR code located on the vial or carton. The QR code will bring up a website; then choose the lookup option, enter the lot number, and the expiration date will be displayed. Another option is to access the website directly: http://www.modernatx.com/covid19vaccine-eua. CDC's expiration date tracking tool (https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/expiration-tracker.pdf) can facilitate documenting expiration dates.

Unpunctured vials: Check the expiration date. Never use expired vaccine.
Punctured vials: Check the beyond-use time. Never use vaccine after the beyond-use time.

With the vial upright, gently swirl the vaccine. **Do NOT shake.** If the vial is shaken, contact the manufacturer. Note: Gently swirl the vaccine before withdrawing subsequent doses.

12 Years of Age and Older
Pfizer-BioNTech COVID-19 Vaccine
Vaccine Preparation and Administration Summary

General Information
Vaccine: Pfizer-BioNTech,12 years of age and older (purple cap)
Use the correct formulation based on the age of the recipient
Diluent: 1.8 mL of 0.9% sodium chloride (normal saline, preservative-free) Use a new vial every time.
Multidose vial: 6 doses per vial
Dosage: 0.3 mL
Prepare the vaccine using a NEW vial of diluent EVERYTIME. Discard the diluent vial and remaining diluent after mixing the vaccine.

Age Indications
12 years of age and older

Thawing Frozen Vaccine
- Frozen vaccine must be thawed before using.
- Thaw vaccine in the refrigerator or at room temperature:
  - **Refrigerator:** Between 2°C and 8°C (36°F and 46°F) Unpunctured vials may be stored in the refrigerator for up to 1 month (31 days).
  - **Room temperature (for immediate use):** Up to 25°C (77°F) Unpunctured vials cannot be kept at room temperature for more than 2 hours (including thaw time).
- Amount of time needed to thaw vaccine varies based on temperature and number of vials.
- **Do NOT** refreeze thawed vaccine.
- Use vials in the refrigerator before removing vials from ultra-cold temperature or freezer storage.
- Use CDC's beyond-use date labels for this vaccine to track storage time at refrigerated and frozen temperatures.

Schedule for Primary Series and Booster Dose
- 2-dose series separated by 21 days*
- Moderately and severely immunocompromised people: Administer an additional Pfizer-BioNTech dose at least 28 days after the initial 2-dose primary series.†
- A primary series started with Pfizer-BioNTech COVID-19 Vaccine should be completed with this product.
- A booster dose, at least 6 calendar months after the last dose of a COVID-19 mRNA primary series‡ (i.e., after the 2nd dose or after the additional [3rd] dose for moderately or severely immunocompromised persons)
  - Should be given to persons 18 years of age and older (Use of heterologous- mix and match - booster doses is allowed)
  - May be given to persons 16 and 17 years of age based on their individual benefits and risks

Administration
Intramuscular (IM) injection in the deltoid muscle

Prepare the Vaccine
Follow aseptic technique. Perform hand hygiene before vaccine preparation, between patients, when changing gloves (if worn), and any time hands become soiled.[1]

Remove vaccine from the storage unit. **Check the vial label to ensure it is the correct formulation based on the age of the recipient. The vial for persons 12 years of age and older has a purple cap and purple border on the label.** Allow vaccine to come to room temperature. Vials can be held at room temperature for up to 2 hours before mixing.

Before mixing, check the:
- expiration date on the vaccine and diluent
- any beyond-use dates/times

NEVER use expired vaccine or diluent. **NEVER** use vaccine after the beyond-use date or times.

With the vaccine at room temperature, gently invert vial 10 times. **Do not shake the vial.** If the vial is shaken, contact the manufacturer. The vaccine is white to off-white in color and may contain opaque particles. Do not use if liquid is discolored.

Using a new, sterile alcohol prep pad for each vial, wipe off the stoppers of the diluent and vaccine vials. Using a 21-gauge (or narrower) needle, **withdraw 1.8 mL** of 0.9% sodium chloride (normal saline, preservative-free) into a mixing syringe. Discard diluent vial and any remaining diluent every time. **Do NOT** use bacteriostatic normal saline or other diluents to mix the vaccine.

COVID-19 Vaccine Expiration Dates

Pfizer Purple Cap (Age 12+)

- Find on vial and tray
- On tray - under lot number that's highlighted in yellow
- On vial - circled in red below



Pfizer Orange Cap (Age 5-11)

- Date printed on vial and tray is **manufacturing date only**
- Use Pfizer Age 5-11 EUA Fact Sheet (Page 3)
- Use Pfizer website

Base expiration date on storage method and manufacturing date. For example:

- If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
- If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.

Pfizer Gray Cap (12+)

- Date printed on vial and tray is **manufacturing date only**
- Use Pfizer Gray Cap (Ages 12+) EUA Fact Sheet (Page 5)
- Use Pfizer website

Base expiration date on storage method and manufacturing date. For example:

- If the manufacturer date is 8/2021 and the doses are stored in an ultra-low-temp freezer, the doses would expire April 30, 2022.
- If the doses are put in the refrigerator November 2, 2021, they would expire 10 weeks from November 2 on January 11, 2022.

Moderna

- Use QR code
- Enter lot number on expiration date checker website

Janssen

- Use QR code
- Enter lot number on expiration date checker website
- Can be used until 11:59 EST on expiry date

CDC Expiration Date Tracking Tool

- Comirnaty/Pfizer Purple Cap (Age 12+) doses can be stored frozen (-20° C) for up to two weeks and/or refrigerated for up to one month
- Pfizer Orange Cap (Age 5-11) doses can be refrigerated for up to 10 weeks
- Moderna doses can be refrigerated for up to 30 days
- Janssen doses can be refrigerated for up to 11 months
- Providers should check the latest expiry information on the manufacturer's website before doses are removed from the unit



COVID-19 Vaccine Expiration Date Tracking Tool

Use this tracking tool to record updated expiration dates for COVID-19 vaccine as additional stability data are available from the manufacturer. When the current expiration date gets close, contact the manufacturer before discarding vaccine. Document the current date, the vaccine lot number, and the updated expiration date in the appropriate columns, including the information source and the name of the person completing this form. Keep this document for 3 years or longer if required by your jurisdiction..

Product name: _____ **Manufacturer:** _____ **Original Expiration Date:** _____

Expiration date info is available at (include all available information from manufacturer; website, app, phone number.)

Date	Lot Number	Updated Expiration Date	Info Source	Name
Example: 09/01/2020	ABC123DEF456	06/30/2021	☒ Website ☐ Barcode	Susie Smith RN

COVID-19 Vaccine and Beyond-use Dates (BUDs)

- CDC has developed tracking labels refrigerators and freezers to help monitor and document cold storage dates
- Assist with documenting transportation time and temperature
- Available for both Moderna and Pfizer/Comirnaty vaccines
- Moderna COVID-19 Vaccine: Beyond Use Date/Time (BUD) Tracking Label for Vaccine During Refrigerator Storage (cdc.gov)
- Pfizer-BioNTech COVID-19 Beyond Use Date/Time (BUD) Tracking Labels for Vaccine During Freezer or Refrigerator Storage (cdc.gov)

Returning Thermal Shipping Containers (Once Empty)

Pfizer (Gray Cap)
- Shippers **DO NOT** need to be returned
- Only controlant data logger needs to be returned

Comirnaty/Pfizer (Purple Cap ONLY)
- Turn off the temperature monitoring device
- Return the shipping containers and temperature monitors
- Return label included with the box
- Instructions on returning Comirnaty/Pfizer thermal shipper

Pfizer (Orange Cap)
- Shippers **DO NOT** need to be returned
- Only controlant data logger needs to be returned

Moderna
- Return using the return label located on the inside of the box

Janssen shippers do not need to be returned

Excess ancillary kit supplies do not need to be returned, can be used for other purposes in facility

Vaccine Process

Vaccines are widely available

- Providers enter COVID-19 vaccine order in ASIIS
- AIPO will approve the order
- Order goes to CDC to Distributor/Manufacturer
- Order is shipped (will show in ASIIS)
- Provider receives shipment of ancillary kit and vaccine (may not be same day)
- Provider logs into ASIIS to mark doses as “received”
- Provider administers vaccine
- Provider reports the administered vaccine to ASIIS through their EHR, State VMS POD application, directly in ASIIS or using Mass Immunization Module in ASIIS
- The dose is subtracted from the ASIIS inventory

ASIIS Information

Placing Orders in ASIIS

- Providers who have an approved onboarding submission are able to order vaccines
- AIPO Train courses
  - How to Place an Order in ASIIS
  - Vaccine Inventory Management - information on ordering and inventory reconciliation
  - Sign up for Dose Accountability Webinar
    - Recordings available any time within AIPO Train course
  - Included in Pandemic Provider course bundle
- Use COVID-19 Vaccine Presentations Job Aid to help make ordering decisions

Vaccine Transfer Process

- Both the sending and receiving providers will email data logger reports to ArizonaVFC@azdhs.gov
- Transfers must be approved in ASIIS prior to moving the doses
    - Enter the transfer in ASIIS prior to moving the doses
        - Information you will need for ASIIS
            1. The organization and facility sending the doses
            2. The organization and facility receiving the doses
            3. The quantity
            4. The lot number
    - When the doses arrive, mark them "received" in ASIIS. Do not administer doses before "receiving" them in the ASIIS inventory
- **Only onboarded, active COVID-19 vaccine providers may receive COVID-19 vaccines**
- Follow the USP transfer guidelines when packing the doses for transfer
    - Once frozen doses have been thawed they cannot go back into a freezer
- Wherever the vaccines are, data loggers must be with them to monitor the temperatures
- The ancillary kit must also be transferred with the doses

Vaccine Wastage

- **If vaccine expires before you can use it:**
  1. Complete the AIPO wastage form (Must be signed by the enrolling provider)
     - Please compile all wasted doses for the week onto one form and submit this form **once a week**, not daily.
  2. Email the completed form to arizonavfc@azdhs.gov
  3. Dispose of the vaccine
- Expired/wasted COVID-19 doses should be disposed of in a sharps container or per the hazardous waste policy in your office
- Tear off the vial labels or mark the identifying information (lot number, NDC number, etc) with a black marker prior to disposing
- Expired/wasted COVID-19 vaccines **DO NOT** go back to McKesson or Pfizer at this time
- How to Account for Wasted/Expired Doses Job Aid

Correcting Negative Doses in ASIIS

Reconciling ASIIS inventory

- Giving more doses than what is in the ASIIS inventory will make the inventory
- negative, which will mean you cannot submit inventory reconciliation
- Only if extracting extra doses from a vial
    - Ex. Extracting 15 doses from Moderna 14-dose vial
- AIPO Train module: Correcting Negative COVID-19 Doses in ASIIS

How to Run Reminder/Recall Report

- ASIIS Reminder/Recall Reports AIPO Train course
- Identify patients due/past due for vaccines
- Schedule patients
- Create letters, postcards, and mailing labels

If your ASIIS Inventory is not accurate

- Doses that have been administered to patients should not be removed from the Reconciliation page (Inventory) in ASIIS
- Troubleshoot why the doses did not decrement
  - Register for Dose Accountability Webinar in AIPO Train
  - Past Dose Accountability Webinar videos in course module
- Job aid to walk you through process of searching/adding/editing patient records manually in ASIIS

Mark doses as *Received* in ASIIS when the doses arrive

- Required regardless what system you use to document vaccine administration (EHR, VMS, ASIIS)
- When the doses arrive, mark them as ***Received*** in ASIIS
  - Log into ASIIS
  - Go to Orders/Transfers> Create/View Orders> Select arrow for Inbound Order/Transfer
  - Verify the expiration date, lot number, and quantity of doses
    - ASIIS may show 12/31/2069 as a placeholder and you must change it
  - Click the ***Receive*** button to receive the doses into the ASIIS Inventory
- After the doses are ***Received*** in ASIIS, you may administer them
- If you administer doses before they are ***Received*** into the ASIIS inventory, they will not decrement from the ASIIS inventory



Funding Source - PAN

- The funding source should be PAN.
- If you have an EHR, your EHR vendor should send the code VXC50. On the user interface side, you will select PAN when administering.
- If you select VFC, State, Private, or something else as the funding source, the doses will not decrement from the ASIIS inventory.

Communication Resources

Granicus Communications (Email Updates)

The AIPO sends granicus updates (email updates) on a variety of topics including COVID-19 vaccines, ASIIS, routine vaccines, etc. This library can be accessed at any time with the above link to view previously sent updates.

Ad Council COVID-19 Vaccination Campaign: It's Up to You

getvaccineanswers.org

- Campaign site for consumers
- Answers common questions
- Provides vaccine information
- Link to Spanish site - www.DeTiDepende.org
- Creative materials that can be shared/used by providers



COVID-19 Vaccine Confidence Toolkit for Rural Jurisdictions

- Print ads
- Posters
- Brochure
- Social media posts
- Online resource guide
- PDFs can be customized using Adobe Acrobat Pro



ADHS COVID-19 Communication Resources

- Posters in English and Spanish (sample here)
- Addressing Misinformation (here)
- Answering Patient Questions (here)
- What to Expect After Getting COVID Vaccine (here)
- What to Expect at Your Vaccine Appointment (here)
- Vaccination Quick Answers (here)
- Answering Common Patient Questions (here)

COVID-19 Vaccine - Providers' Toolkit

- Order Form to request materials for your facility

HHS Video "Tell Me More About Vaccines"

The video answers commonly asked questions about the COVID-19 vaccine. The video shares why vaccines are so important and provides expert commentary and graphic illustration to help viewers understand the science of vaccine development. Tune in to hear from various experts, including Dr. Anthony Fauci (NIH), Dr. Stephen Hahn (FDA), and Dr. Robert Kadlec (ASPR), on the steps researchers and scientists are taking to develop a safe and effective vaccine. You are encouraged to add the video link to your website or promote it on social media.



FDA Emergency Use Authorization for Vaccines Explained

- What is an Emergency Use Authorization?
- Are the COVID-19 vaccines rigorously tested?
- What safety and effectiveness data are required to be submitted to FDA for an EUA request for a vaccine intended to prevent COVID-19?

CDC COVID-19 Vaccination Communication Toolkits

- For Medical Centers, Clinics, Pharmacies, and Clinicians
- For Healthcare Professionals and Pharmacists
- For LTCF Administrators and Leadership
- For Employers of Essential Workers
- For Staff of Organizations Serving Communities
- Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit

The toolkit contains a variety of resources that you can use virtually or in person (with proper COVID-19 safety precautions):

- Posters
- FAQ
- Key messages
- Slide decks



Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit

Updated May 15, 2021 Print

As parents' most trusted source of information on vaccines, pediatric healthcare professionals play a critical role in helping parents/guardians understand the importance of COVID-19 vaccination and assuring them that COVID-19 vaccines are safe and effective.

Your strong recommendation is critical for vaccine acceptance. Tell parents/guardians how important COVID-19 vaccines are to protecting their children's health.

Remind parents that after their family is fully vaccinated against COVID-19, they may start to do some things they had stopped doing because of the pandemic.

Even if you are not administering COVID-19 vaccines, you can help parents/guardians feel confident in choosing to get their children vaccinated against COVID-19 by addressing their questions and assuring them of the safety and effectiveness of COVID-19 vaccines.

The materials on this page will help you share clear and accurate information about COVID-19 vaccines when starting or continuing conversations with parents/guardians, as well as information for those who choose not to vaccinate their child.

Only healthcare professionals enrolled as vaccination providers directly through a health practice or organization can legally store, handle, and administer COVID-19 vaccine in the United States. Learn more about becoming a COVID-19 Vaccination Provider: How to Enroll as a COVID-19 Vaccination Provider.

COVID-19 Vaccination of Minors

Patients, parents, and guardians may have questions about consent for vaccination for minors recommended to receive a COVID-19 vaccine. Learn more at: Pfizer-BioNTech COVID-19 Vaccine.

Provider Resources for Patient Conversations About COVID-19 Vaccines

- How to talk to your patients about COVID-19 vaccination

CDC's Key Points to Communicate to Your Patients:

- COVID-19 vaccines are safe and effective.
- Individuals 12 and up are all eligible to get a COVID-19 vaccination.
- There are many locations to find a COVID-19 vaccine.
- Having some side effects after vaccination is normal.
- You are not fully vaccinated until 2 weeks after the 2nd dose of a two-dose vaccine or 2 weeks after a one-dose vaccine.



CDC COVID-19 Vaccine Web Pages for the general public

- Benefits of Getting a COVID-19 Vaccine
- How COVID-19 Vaccines Work
- Frequently Asked Questions about COVID-19 Vaccination
- Understanding MRNA vaccines
- What to Expect at Your Appointment to Get Vaccinated for COVID-19
  - Translated in many languages
- When You've Been Fully Vaccinated
- Webpage COVID-19 Vaccines for Children and Teens



FAQs

FAQs

Q: If I am a VFC provider and already have an ASIIS PIN, do I still need to onboard?

- A: Yes. If a facility location wants to administer COVID-19 vaccines, they will need to onboard and sign the CDC COVID-19 Agreement. The VFC Program and the COVID-19 vaccine program are separate programs with separate signed Agreements.

Q: How do I order COVID-19 vaccines in ASIIS?

- A: Onboarded and active COVID-19 providers can follow the instructions in this job aid on how to place orders

Q: Where can I find these slides?

- A: These slides can be found at azdhs.gov/covid19vaccine on the Provider Resources page. You can also find a link to the slides and the most recent recording in the Pandemic Provider Weekly Brown Bag course in AIPO Train.

THANK YOU!